Effects of different doses of ticagrelor on platelet aggregation and endothelial function in diabetic patients with stable coronary artery disease

References

• Waksman R, Maya J, Angiolillo DJ, Carlson GF, Teng R, Caplan RJ, Ferdinand KC. Ticagrelor versus clopidogrel in black patients with stable coronary artery disease: prospective, randomized, open-label, multiple-dose, crossover pilot study. Circ Cardiovasc Interv. 2015;8(7):e002232.
   PubMed Web of Science ®Google Scholar
• Bonello L, Laine M, Kipson N, Mancini J, Helal O, Fromonot J, Gariboldi V, Condo J, Thuny F, Frere C, et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol. 2014;63:872–877.
   PubMed Web of Science ®Google Scholar
• Tanguay JF, Bell AD, Ackman ML, Bauer RD, Cartier R, Chan WS, Douketis J, Roussin A, Schnell G, Verma S, et al. Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy. Can J Cardiol. 2013;29(11):1334–1345.
   PubMed Web of Science ®Google Scholar
• Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, et al. ACC/AHA task force members. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American college of cardiology/American heart association task force on practice guidelines. Circulation. 2014;130(25):2354–2394.
   PubMed Web of Science ®Google Scholar
• Choi KN, Jin HY, Shin HC, Park YA, Seo JS, Jang JS, Yang TH, Kim DK, Kim DS. Comparison of the antiplatelet effects of once and twice daily low-dose ticagrelor and clopidogrel after percutaneous coronary intervention. Am J Cardiol. 2017;120(2):201–206.
   PubMed Web of Science ®Google Scholar
• Guo LZ, Kim MH, Jin CD, Lee JY, Yi SJ, Park MK, Cho YR, Park TH. Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects. Platelets. 2015;26(6):563–569.
   PubMed Web of Science ®Google Scholar
• Hiasa Y, Teng R, Emanuelsson H. Pharmacodynamics, pharmacokinetics and safety of ticagrelor in Asian patients with stable coronary arterydisease. Cardiovasc Interv Ther. 2014;29(4):324–333.
   PubMedGoogle Scholar
• Xue HJ, Shi J, Liu B, Wang DY, Dong ZX, Guo H, Kong YH, Sheng L, Shao Q, Sun DH, et al. Comparison of half- and standard-dose ticagrelor in Chinese patients with NSTE-ACS. Platelets.2016;2:1–6.
   Google Scholar
• He MJ, Liu B, Sun DH, Pan YJ, Zheng WB, Shi J, Zhao SQ, Dong XW, Lu S, Li MH, et al. One-quarter standard-dose ticagrelor better than standard-dose clopidogrel in Chinese patients with stable coronary artery disease: A randomized, single-blind, crossover clinical study. Int J Cardiol. 2016;215:209–213.
   PubMed Web of Science ®Google Scholar
• Li H, Butler K, Yang L, Yang Z, Teng R. Pharmacokinetics and tolerability of single and multiple doses of ticagrelor in healthy Chinese subjects: an open-label, sequential, two-cohort, single-centre study. Clin Drug Investig. 2012;32(2):87–97.
   PubMed Web of Science ®Google Scholar
• Sweeny JM, Angiolillo DJ, Franchi F, Rollini F, Waksman R, Raveendran G, Dangas G, Khan ND, Carlson GF, Zhao Y, et al. Impact of diabetes mellitus on the pharmacodynamic effects of ticagrelor versus clopidogrel in troponin-negative acute coronary syndrome patients undergoing ad hoc percutaneous coronary intervention. J Am Heart Assoc. 2017;6(4): e005650.
   PubMedGoogle Scholar
• Shah AS, Urbina EM. Vascular and endothelial function in youth with type 2 diabetes mellitus. Curr Diab Rep. 2017;17(6):36.
   PubMed Web of Science ®Google Scholar
• Eltzschig HK, Sitkovsky MV, Robson SC. Purinergic signaling during inflammation. N Engl J Med. 2012;367:2322–2333.
   PubMed Web of Science ®Google Scholar
• Li Z, Li Y, Zhang T, Miao W, Su G. Comparison of the influence of ticagrelor and clopidogrel on inflammatory biomarkers and vascular endothelial function for patients with ST-segment elevation myocardial infarction receiving emergency percutaneous coronary intervention: study protocol for a randomized controlled trial. Trials.2016;17:75.
   PubMed Web of Science ®Google Scholar
• Fromonot J, Dignat-Georges F, Rossi P, Mottola G, Kipson N, Ruf J, Bonello L, Guieu R, Paganelli F. Ticagrelor improves peripheral arterial function in acute coronary syndrome patients: relationship with adenosine plasma level. J Am Coll Cardiol. 2016;67(16):1967–1968.
   PubMed Web of Science ®Google Scholar
• Torngren K, Ohman J, Salmi H, Larsson J, Erlinge D. Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. Cardiology. 2013;124(4):252–258.
   PubMed Web of Science ®Google Scholar
• Zhang HZ, Kim MH, Jeong YH. Predictive values of post-clopidogrel platelet reactivity assessed by different platelet function tests on ischemic events in East Asian patients treated with PCI. Platelets. 2014;25:292–299.
   PubMed Web of Science ®Google Scholar
• Harrison P, Frelinger III AL, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory. Thromb Res. 2007;120:323–336.
   PubMed Web of Science ®Google Scholar
• Price MJ, Angiolillo DJ, Teirstein PS, Lillie E, Manoukian SV, Berger PB, Tanguay JF, Cannon CP, Topol EJ. Platelet reactivity and cardiovascular outcomes after percutaneous coronary intervention: a time-dependent analysis of the gauging responsiveness with a Verifynow P2Y12 assay: impact on thrombosis and safety (GRAVITAS) trial. Circulation. 2011;124:1132–1137.
   PubMed Web of Science ®Google Scholar
• Us T, Bonello L, Aradi D, Mj P, Yh J, Dj A, Gw S, Curzen N, Geisler T, Ten BJ, et al. Working group on on-treatment platelet reactivity. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol. 2013;62:2261–2273.
   PubMed Web of Science ®Google Scholar
• Chong Tou TJ, Liu PM, Wang JF, Sio Cham ZC, O U Yf LS. ZW, Lei Put PZ, Lei Sok SM, Zhou SX, Wu W. Impact of Novel P2Y12 Receptor Inhibitors on Platelet Reactivity in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention. Zhonghua Xin Xue Guan Bing Za Zhi. 2016;44(2):138–143.
   PubMedGoogle Scholar
• Li P, Yang Y, Chen T, Liu Y, Cao A, Liu J, Wang Z, Zhao X, Qin Y, Ma L. Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. Sci Rep. 2015;5:13789.
   PubMed Web of Science ®Google Scholar
• Jeong YH, Bliden KP, Antonino MJ, Park KS, Tantry US, Gurbel PA. Usefulness of the Verifynow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogreltherapies. Am Heart J. 2012;164(1):35–42.
   PubMed Web of Science ®Google Scholar
• Jax T, Stirban A, Terjung A, Esmaeili H, Berk A, Thiemann S, Chilton R, von Eynatten M, Marx N. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes. Cardiovasc Diabetol. 2017;16:13.
   PubMed Web of Science ®Google Scholar
• Armstrong D, Summers C, Ewart L, Nylander S, Sidaway JE, van Giezen JJ. Characterization of the adenosine pharmacology of ticagrelor reveals therapeutically relevant inhibition of equilibrative nucleoside transporter 1. J Cardiovasc Pharmacol Ther. 2014;19:209–219.
   PubMed Web of Science ®Google Scholar
• Bonello L, Laine M, Kipson N, Mancini J, Helal O, Fromonot J, Gariboldi V, Condo J, Thuny F, Frere C, et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol. 2014;63:872–877.
   PubMed Web of Science ®Google Scholar
• Storey RF, Angiolillo DJ, Patil SB, Desai B, Ecob R, Husted S, Emanuelsson H, Cannon CP, Becker RC, Wallentin L. Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. J Am Coll Cardiol. 2010;56:1456–1462.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577–2585.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045–1057.
   PubMed Web of Science ®Google Scholar
• Teng R, Butler K. Pharmacokinetics, pharmacodynamics, and tolerability of single and multiple doses of ticagrelor in Japanese and Caucasian volunteers. Int J Clin Pharmacol Ther. 2014;52:478–491.
   PubMed Web of Science ®Google Scholar
• Levine GN, Jeong YH, Goto S, Anderson JL, Huo Y, Mega JL, Taubert K, Smith SC Jr. Expert consensus document: world heart federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol. 2014;11(10):597–606.
   PubMed Web of Science ®Google Scholar
• Capodanno D, Angiolillo DJ. Impact of race and gender on antithrombotic therapy. Thromb Haemost. 2010;104(3):471–484.
   PubMed Web of Science ®Google Scholar
• Liang ZY, Han YL, Zhang XL, Li Y, Yan CH, Kang J. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation. EuroIntervention. 2013;9:316–327.
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Badimon JJ, Bhatt DL, Herbert JM, Luscher TF. Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease. Vasc Med. 2007;12(2):113–122.
   PubMed Web of Science ®Google Scholar
• McClung JA, Kruger AL, Ferraris A, Vanella L, Tsenovoy P, WeissMB, Abraham NG. Usefulness of clopidogrel to protect against diabetes-induced vascular damage. Am J Cardiol. 2010;105(7):1014–1018.
   PubMed Web of Science ®Google Scholar
• Torngren K, Ohman J, Salmi H, Larsson J, Erlinge D. Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. Cardiology. 2013;124:252–258.
   PubMed Web of Science ®Google Scholar
• Kim HK, Jeong MH, Lim KS, Kim JH, Lim HC, Kim MC, Hong YJ, Kim SS, Park KH, Chang KS. Effects of ticagrelor on neointimal hyperplasia and endothelial function, compared with clopidogrel and prasugrel, in a porcine coronary stent restenosis model. Int J Cardiol. 2017;240:326–331.
   PubMed Web of Science ®Google Scholar
• Jeong HS, Hong SJ, Cho SA, Kim JH, Cho JY, Lee SH, Joo HJ, Park JH, Yu CW, Lim DS. Comparison of ticagrelor versus prasugrel for inflammation, vascular function, and circulatingendothelial progenitor cells in diabetic patients with non-st-segment elevation acute coronary syndrome requiring coronary stenting: a prospective, randomized, crossover trial. JACC Cardiovasc Interv. 2017;10(16):1646–1658.
   PubMed Web of Science ®Google Scholar